These results suggest that liver cancer cells expressing CD133 are associated with radioresistance and CSCs-targeting therapeutic approaches involving destruction of CD133+ liver CSCs may be promising for use in HCC treatment. The gene discussed is PROM1; the disease is hepatocellular carcinoma.